Martin Memorial Medical Center INC
Martin Memorial Medical Center INC was paid $26.03M by Medicaid between Jan 2018 and Dec 2024, across 319 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoMARTIN MEMORIAL MEDICAL CENTER INC
STUART, FL 34994
STUART, FL 34994
33aNPI1194790055assigned 02/22/2006
33bProvider typeSpecialist
28Total paid$26.03M
24GClaims1,141,011
24DCodes billed319
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in Florida
Rank by total paid#1 of 553
Median peer was paid$31K
This provider vs. median833×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LARAWAY, DENNIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 107,495 | $1.80M | |
| 2019 | 234,009 | $5.34M | |
| 2020 | 197,942 | $3.28M | |
| 2021 | 254,709 | $5.09M | |
| 2022 | 244,855 | $6.26M | |
| 2023 | 78,325 | $3.24M | |
| 2024incomplete | 23,676 | $1.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 48,754 | 42,622 | $4.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.6% | 36,184 | 32,514 | $2.50M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 8.9% | 26,410 | 8,339 | $2.33M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 8.1% | 26,714 | 7,829 | $2.10M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.9% | 30,423 | 24,339 | $2.05M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.2% | 25,380 | 7,353 | $1.88M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 6,301 | 5,488 | $858K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 7,607 | 6,247 | $796K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.8% | 15,420 | 11,462 | $721K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 2,785 | 2,383 | $382K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.3% | 30,563 | 20,566 | $333K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 4,407 | 4,075 | $306K |
307 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,969 | $229K |
| G0378 | Hospital observation service, per hour | <1% | 12,234 | $197K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,855 | $190K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,342 | $189K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 34,697 | $188K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,429 | $183K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,208 | $178K |
| 80053 | Comprehensive metabolic panel | <1% | 28,785 | $171K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 7,398 | $171K |
| 97162 | <1% | 2,316 | $160K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,046 | $152K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,567 | $146K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 5,718 | $139K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,647 | $129K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,865 | $120K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,353 | $113K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,580 | $108K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,894 | $108K |
| 59025 | Fetal non-stress test | <1% | 1,339 | $105K |
| A6216 | Gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 7,125 | $96K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,113 | $95K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,093 | $92K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,802 | $88K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,706 | $84K |
| 87088 | <1% | 16,885 | $82K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,593 | $81K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,419 | $80K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,603 | $79K |
| 87486 | <1% | 2,048 | $79K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,143 | $78K |
| 97161 | <1% | 1,722 | $76K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,444 | $71K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,987 | $71K |
| 97166 | <1% | 765 | $67K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,963 | $65K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 417 | $65K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,389 | $65K |
| 97014 | <1% | 396 | $63K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,402 | $59K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,086 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 57,316 | $54K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,824 | $48K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 796 | $47K |
| 92523 | <1% | 568 | $47K | |
| 71045 | Radiologic examination, chest; single view | <1% | 16,831 | $46K |
| 87070 | <1% | 4,158 | $45K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,170 | $45K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,202 | $45K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 718 | $45K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,627 | $42K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,024 | $41K |
| 81025 | <1% | 16,432 | $40K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,822 | $40K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,304 | $38K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,529 | $38K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,598 | $37K |
| 73610 | <1% | 1,704 | $36K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,447 | $35K |
| 76830 | Ultrasound, transvaginal | <1% | 924 | $35K |
| 73630 | <1% | 2,378 | $34K | |
| 81003 | <1% | 13,397 | $34K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,159 | $34K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,441 | $33K |
| 76801 | <1% | 1,846 | $33K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,645 | $33K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,003 | $31K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,931 | $29K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 583 | $29K |
| 97116 | <1% | 2,351 | $29K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 814 | $28K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,505 | $28K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 469 | $28K |
| 73564 | <1% | 2,177 | $28K | |
| 81001 | <1% | 26,773 | $28K | |
| 84484 | <1% | 16,487 | $27K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,198 | $26K |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 633 | $26K |
| 76775 | <1% | 578 | $26K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 579 | $26K |
| 82948 | <1% | 2,163 | $26K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,010 | $25K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,328 | $25K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,750 | $25K |
| 85610 | <1% | 13,848 | $25K | |
| 90714 | <1% | 963 | $24K | |
| 73130 | <1% | 1,772 | $24K | |
| 73110 | <1% | 1,251 | $24K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,639 | $24K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,441 | $22K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,128 | $22K |
| 71250 | <1% | 701 | $22K | |
| 73030 | <1% | 1,571 | $21K | |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 711 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 347 | $21K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,865 | $21K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 318 | $21K |
| 85027 | <1% | 9,351 | $21K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,072 | $20K |
| 76641 | <1% | 353 | $20K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 378 | $18K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 961 | $18K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,027 | $18K |
| 82550 | <1% | 9,915 | $18K | |
| 72110 | <1% | 1,833 | $17K | |
| 85730 | <1% | 9,335 | $17K | |
| 74018 | <1% | 928 | $16K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,424 | $16K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,403 | $15K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 584 | $15K |
| 87040 | <1% | 8,175 | $14K | |
| 86850 | <1% | 1,906 | $14K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 241 | $14K |
| 82962 | <1% | 6,376 | $14K | |
| 82553 | <1% | 7,372 | $14K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 993 | $14K |
| 73080 | <1% | 726 | $14K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 600 | $13K |
| 74019 | <1% | 1,963 | $13K | |
| 93971 | <1% | 854 | $13K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,644 | $12K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 256 | $12K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 276 | $12K |
| 80076 | <1% | 13,638 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,442 | $11K |
| 76536 | <1% | 199 | $11K | |
| 84702 | <1% | 3,334 | $11K | |
| 80061 | Lipid panel | <1% | 8,626 | $11K |
| 87210 | <1% | 2,104 | $10K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 394 | $10K |
| 12011 | <1% | 445 | $10K | |
| 97165 | <1% | 443 | $10K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,262 | $10K |
| 83735 | <1% | 6,632 | $9K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,695 | $9K |
| 83690 | <1% | 14,645 | $9K | |
| 73502 | <1% | 905 | $9K | |
| 96376 | <1% | 3,076 | $9K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 671 | $8K |
| 92567 | <1% | 235 | $8K | |
| 83605 | <1% | 12,251 | $8K | |
| 12001 | <1% | 422 | $8K | |
| 87186 | <1% | 6,469 | $8K | |
| 72131 | <1% | 211 | $8K | |
| C1769 | Guide wire | <1% | 1,269 | $8K |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 902 | $8K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,645 | $7K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,894 | $7K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 77 | $7K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 644 | $7K |
| 99152 | <1% | 1,086 | $7K | |
| 87205 | <1% | 2,938 | $7K | |
| 83880 | <1% | 3,165 | $7K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 935 | $7K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,048 | $7K |
| 72050 | <1% | 703 | $6K | |
| 85379 | <1% | 3,504 | $6K | |
| 29130 | <1% | 60 | $6K | |
| 99205 | Prolong outpt/office vis | <1% | 77 | $5K |
| 70491 | <1% | 45 | $5K | |
| 86140 | <1% | 4,847 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,309 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,210 | $5K |
| 77072 | <1% | 120 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 69 | $5K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 127 | $5K |
| 92587 | <1% | 294 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,245 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,278 | $4K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 177 | $4K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 799 | $4K |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 1,962 | $4K |
| 84100 | <1% | 3,461 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 581 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,243 | $4K |
| 82140 | <1% | 1,253 | $4K | |
| 87634 | <1% | 1,328 | $3K | |
| 76818 | <1% | 39 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 89 | $3K |
| 73590 | <1% | 330 | $3K | |
| 82150 | <1% | 6,856 | $3K | |
| 94664 | <1% | 2,753 | $3K | |
| 86900 | <1% | 2,971 | $3K | |
| 98966 | <1% | 110 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 118 | $3K |
| 84439 | <1% | 2,352 | $3K | |
| 98967 | <1% | 64 | $3K | |
| 87507 | <1% | 211 | $3K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 71 | $3K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 216 | $3K |
| 73090 | <1% | 223 | $3K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 263 | $3K |
| 92557 | <1% | 23 | $3K | |
| 29125 | <1% | 463 | $3K | |
| 93970 | <1% | 70 | $3K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,580 | $2K |
| 87581 | <1% | 2,049 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,056 | $2K |
| 82607 | <1% | 1,916 | $2K | |
| 70486 | <1% | 80 | $2K | |
| 80069 | <1% | 643 | $2K | |
| 86901 | <1% | 2,971 | $2K | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 150 | $2K |
| 82270 | <1% | 254 | $2K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 169 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,465 | $2K |
| 97163 | <1% | 13 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 40 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 87 | $2K |
| 85652 | <1% | 3,033 | $2K | |
| 84112 | <1% | 12 | $2K | |
| 36430 | <1% | 42 | $2K | |
| 82570 | <1% | 2,121 | $2K | |
| 86308 | <1% | 193 | $2K | |
| 84703 | <1% | 3,526 | $2K | |
| 71101 | <1% | 163 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 70 | $2K |
| 82247 | <1% | 315 | $1K | |
| A6248 | Hydrogel dressing, wound filler, gel, per fluid ounce | <1% | 881 | $1K |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 102 | $1K |
| A6219 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 429 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 439 | $1K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 509 | $1K |
| 72100 | <1% | 198 | $1K | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 100 | $1K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 58 | $1K |
| 76870 | <1% | 33 | $1K | |
| 83540 | <1% | 913 | $1K | |
| 72141 | <1% | 26 | $1K | |
| 10060 | <1% | 49 | $965.99 | |
| 91300 | <1% | 128 | $913.94 | |
| 51701 | <1% | 892 | $895.99 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 43 | $872.37 |
| 76813 | <1% | 37 | $866.16 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 22 | $791.77 |
| 82728 | <1% | 728 | $762.62 | |
| 72170 | <1% | 71 | $588.65 | |
| 87807 | <1% | 913 | $520.26 | |
| 73140 | <1% | 28 | $510.36 | |
| 84481 | <1% | 737 | $507.66 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 125 | $473.55 |
| 93880 | <1% | 27 | $473.36 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 48 | $434.14 |
| C1729 | Catheter, drainage | <1% | 114 | $412.77 |
| 92579 | <1% | 20 | $403.68 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 88 | $390.00 |
| 96367 | <1% | 199 | $389.20 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,089 | $377.80 |
| 82805 | <1% | 16 | $355.57 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 147 | $335.50 |
| 12002 | <1% | 25 | $327.86 | |
| 82043 | <1% | 896 | $320.05 | |
| A6217 | Gauze, non-impregnated, non-sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 241 | $255.45 |
| 85046 | <1% | 164 | $249.56 | |
| 51798 | <1% | 79 | $239.29 | |
| 84145 | <1% | 661 | $224.57 | |
| A6252 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 477 | $215.12 |
| 72072 | <1% | 34 | $214.50 | |
| 86923 | <1% | 165 | $209.26 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 96 | $181.43 |
| 82248 | <1% | 575 | $180.16 | |
| 84550 | <1% | 717 | $177.39 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 30 | $173.89 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 50 | $167.06 |
| 0001A | <1% | 377 | $157.54 | |
| 76937 | <1% | 174 | $150.00 | |
| 88300 | <1% | 51 | $146.01 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 14 | $127.21 |
| 84156 | <1% | 807 | $122.28 | |
| 0002A | <1% | 406 | $114.58 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 43 | $109.98 |
| 82010 | <1% | 140 | $106.91 | |
| 82746 | <1% | 205 | $100.50 | |
| 80164 | <1% | 76 | $99.24 | |
| 70360 | <1% | 12 | $97.74 | |
| 73552 | <1% | 31 | $55.16 | |
| 1160F | <1% | 2,116 | $48.57 | |
| 80074 | <1% | 30 | $37.10 | |
| 94760 | <1% | 484 | $33.42 | |
| 83970 | <1% | 46 | $29.25 | |
| 83615 | <1% | 212 | $26.24 | |
| 83550 | <1% | 384 | $20.02 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 38 | $18.54 |
| 88304 | <1% | 221 | $13.15 | |
| 80047 | <1% | 18 | $11.91 | |
| 3078F | 0% | 930 | $0.00 | |
| 1159F | 0% | 2,116 | $0.00 | |
| 0353U | 0% | 108 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 79 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 88 | $0.00 |
| 85014 | 0% | 19 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 30 | $0.00 |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | 0% | 27 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 76 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 27 | $0.00 |
| 3077F | 0% | 15 | $0.00 | |
| 29515 | 0% | 30 | $0.00 | |
| 1125F | 0% | 833 | $0.00 | |
| 3079F | 0% | 105 | $0.00 | |
| 3074F | 0% | 1,246 | $0.00 | |
| 85018 | 0% | 20 | $0.00 | |
| 80177 | 0% | 15 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 300 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 14 | $0.00 |
| 73060 | 0% | 14 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 29 | $0.00 |
| 88307 | 0% | 19 | $0.00 | |
| 86780 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLARAWAY, DENNIS (EXECUTIVE VP CHIEF FINANCE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.